Intervention

Agomelatine

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 8 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials8

Recruiting0

Common conditions9

Lead sponsors shown8

Clinical trials

8 shown

Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I)NCT07011693 · 2025-06-20

NOT_YET_RECRUITING

A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in SchizophreniaNCT05646264 · 2023-01-01

UNKNOWN

A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With AgomelatineNCT04589143 · 2020-10-01

COMPLETED

Pharmacovigilance in Gerontopsychiatric PatientsNCT02374567 · 2015-01-01

TERMINATED

Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)NCT01483053 · 2014-01-01

UNKNOWN

A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous MedicationNCT01488071 · 2012-01-01

COMPLETED

A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)NCT00463242 · 2007-03-01

COMPLETED

The Effect of Agomelatine or Fluoxentine on Heart Rate Variability in Patients With Major Depressive DisorderNCT00451490 · 2006-10-01

WITHDRAWN

Common conditions

Major Depressive Disorder3 Major Depressive Disorder (MDD)2 Schizophrenia2 Anxiety Disorders1 Dementia1 Depression1 Depressive Disorder, Major1 Negative Symptoms in Schizophrenia1 Psychosomatic Disorders1

Leading sponsors

Baker Heart and Diabetes Institute1 Central South University1 H. Lundbeck A/S1 Hannover Medical School1 National Taiwan University Hospital1 Novartis1 Shanghai Mental Health Center1 Xinyu Zhou1

Trial status mix

COMPLETED3

UNKNOWN2

NOT_YET_RECRUITING1

TERMINATED1

WITHDRAWN1

Phase mix

PHASE44

PHASE33

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.